Taiwan Liposome Company, Ltd. (TLC) Stock Analysis
DELISTED
What happened to Taiwan Liposome Company, Ltd. (TLC) stock?
Taiwan Liposome Company, Ltd. (TLC) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Taiwan Liposome Company, Ltd. (TLC). Taiwan Liposome Company, Ltd. (TLC) is a biopharmaceutical company specializing in the development of novel nanomedicines. Utilizing its proprietary lipid-based drug delivery system, TLC aims to improve the efficacy and safety profiles of pharmaceutical products.
Last analyzed: Mar 18, 2026Taiwan Liposome Company, Ltd. (TLC) Healthcare & Pipeline Overview
Taiwan Liposome Company, Ltd. ADR Information Sponsored
Taiwan Liposome Company, Ltd. (TLC) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy TLC shares?
No. TLC stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for TLC elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TLC stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Taiwan Liposome Company, Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.